Why the study?
This study aimed to investigate the mechanism by which Caveolin-1 deficiency leads to cardiac dysfunction.
Does Cav-1 deficiency induce cardiac dysfunction via the AdipoR1-AMPK-mTOR autophagy pathway in experimental models?
Does Cav-1 deficiency induce cardiac dysfunction via the AdipoR1-AMPK-mTOR autophagy pathway in experimental models?
Cav-1 deficiency induces cardiac dysfunction by suppressing autophagy via the AdipoR1-AMPK-mTOR pathway, highlighting it as a potential therapeutic target.
Highlights Cav-1 as potential therapeutic target in HF; leaves open clinical translation from experimental models.**[[1]](https://pubmed.ncbi.nlm.nih.gov/41591548/)[[1]](https://pubmed.ncbi.nlm.nih.
OBJECTIVE AND DESIGN: This study aimed to investigate the mechanism by which Caveolin-1 (Cav-1) deficiency leads to cardiac dysfunction, utilizing both in vivo and in vitro experimental models. MATERIAL OR SUBJECTS: Experiments used 43-52-week-old wild-type (WT) and Cav-1 knockout (Cav-1 TREATMENT: In vivo, Cav-1 METHODS: Cardiac function was assessed by echocardiography (LVEF, LVFS). Protein expression was analyzed via western blotting and immunofluorescence. Autophagic flux was measured using mRFP-GFP-LC3B lentivirus. Apoptosis was evaluated by TUNEL staining and flow cytometry. Data are mean ± SD; statistical analysis used t-tests/ANOVA. RESULTS: Cav-1 CONCLUSIONS: Cav-1 deficiency induces cardiac dysfunction by suppressing autophagy via the AdipoR1-AMPK-mTOR pathway, highlighting Cav-1 as a potential therapeutic target for cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
An et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: